SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Kosan BioSciences -- KOSN
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: rkrw who wrote (79)5/15/2002 2:56:39 PM
From: Biomaven  Read Replies (1) of 933
 
This report confirms that they are at 90mg/m2 in the Phase I. If my calculations are correct this is comparable to the 30 mg/kg that produced excellent results in mice.

Note that the 3mg/m2 MTD for Novartis's EPO B doesn't in and of itself mean they have a tox problem there - EPO B was much more potent in animal studies (but comparatively even more toxic). But I wouldn't be surprised if the competitors do run into tox issues - certainly in animal models KOSN's drug had a way better therapeutic index. I hadn't seen the Phase I results from the competitors yet - they look very strong assuming a reasonable number of people in their trials. I would expect KOSN's drug to do even better, though.

Lets see what we get from ASCO, although it's probably too early in the trial to expect much yet.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News